Replies to post #220492 on Biotech Values

[DewDiligence]

EPIX acquires RLM for $3.19/sh* in stock—a 3% discount to yesterday’s close:

https://www.prnewswire.com/news-releases/agreement-reached-for-essa-pharma-to-acquire-realm-therapeutics-300851546.html

This is effectively a financing transaction for EPIX insofar as EPIX is buying RLM for its approximate cash value per share. The nominal deal price is $21.5M.

(RLM used to trade on the London exchange as RLM.L.)

*Based on EPIX’s 5/15/19 closing price.